P
PTC Therapeutics Inc (PTCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$63.49
+0.13 (+0.21%)
Market Cap: $5.30B
Last updated: Nov 17, 2026 at 11:06 AM ET
PTC Therapeutics Inc (PTCT) Valuation Multiples
PTC Therapeutics (PTCT) trades at 5.2x sales. Its P/S of 5.2x is above its 5-year median of 3.7x. Its forward P/E is 19.0x.
Current Multiples
Its enterprise value is 31.0x its EBITDA.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 19.0x |
| Price to sales | 5.2x |
| EV/EBITDA | 31.0x |
| PEG | N/A |
| FCF yield | -0.8% |
Historical Medians
Against its 10-year medians, its P/S is in line.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 5.2x | 3.7x | 5.2x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 2.2x in 2023 to 10.5x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $75.96 | 10.0x | 3.4x | N/A |
| 2024 | $45.14 | N/A | 4.3x | N/A |
| 2023 | $27.56 | N/A | 2.2x | N/A |
| 2022 | $38.17 | N/A | 3.9x | N/A |
| 2021 | $39.83 | N/A | 5.2x | N/A |
| 2020 | $61.03 | N/A | 10.5x | 8.5x |
| 2019 | $48.03 | N/A | 8.8x | 4.6x |
| 2018 | $34.32 | N/A | 6.0x | 4.9x |
| 2017 | $16.68 | N/A | 3.4x | 4.5x |
| 2016 | $10.91 | N/A | 4.5x | 3.1x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PTCT
What is PTCT's forward P/E ratio?
PTC Therapeutics has a forward P/E ratio of 19.0x.
Is PTCT stock overvalued?
GNG's valuation label for PTCT is Fairly valued.
What is PTCT's price to sales ratio?
PTC Therapeutics has a price to sales ratio of 5.2x.
PTCT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors